Compare AbCellera Biologics Inc (ABCL) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs PepsiCo, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.23 (market cap $2.35B), while PepsiCo, Inc. trades at $143.7 (market cap $198.15B). The key difference: PepsiCo, Inc. is far larger — about 84.3× AbCellera Biologics Inc's market cap, and PepsiCo, Inc. pays a 4.08% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | PEP | |
|---|---|---|
Market Cap | $2.35B | $198.15B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $170.44 |
52-Week Low | $2.78 | $133.81 |
Enterprise Value | $1.99B | $240.05B |
Dividend Yield | — | 4.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
PepsiCo (PEP) trades at $143.66, up 0.26% on the day, with a bullish technical signal and strong profitability metrics including a 54.06% gross margin and 43.92% ROE. Recent earnings have consistently beaten estimates, and the company maintains a solid cash flow profile. News highlights a strategic price reduction on snacks to address consumer pushback and a focus on North American recovery.
The outlook is positive with a consensus price target of $161.73, implying potential upside. Key risks include competitive pressures and sensitivity to consumer spending. Analyst sentiment is mixed but leans bullish, supported by institutional accumulation and a sustainable dividend yield near 4%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
